"Nitric Oxide Donors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A diverse group of agents, with unique chemical structures and biochemical requirements, which generate NITRIC OXIDE. These compounds have been used in the treatment of cardiovascular diseases and the management of acute myocardial infarction, acute and chronic congestive heart failure, and surgical control of blood pressure. (Adv Pharmacol 1995;34:361-81)
| Descriptor ID |
D020030
|
| MeSH Number(s) |
D27.505.519.656 D27.505.954.411.590
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nitric Oxide Donors".
Below are MeSH descriptors whose meaning is more specific than "Nitric Oxide Donors".
This graph shows the total number of publications written about "Nitric Oxide Donors" by people in this website by year, and whether "Nitric Oxide Donors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 2 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 5 | 0 | 5 |
| 2004 | 5 | 3 | 8 |
| 2005 | 3 | 0 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 3 | 1 | 4 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 1 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nitric Oxide Donors" by people in Profiles.
-
Jeddi S, Kashfi K, Ghasemi A. The potential role of nitrate, a nitric oxide donor, in the prevention and treatment of diabetic osteoporosis. Front Endocrinol (Lausanne). 2025; 16:1480838.
-
Bahadoran Z, Mirmiran P, Hosseinpanah F, Kashfi K, Ghasemi A. Nitric oxide-based treatments improve wound healing associated with diabetes mellitus. Med Gas Res. 2025 Mar 01; 15(1):23-35.
-
Bahadoran Z, Mirmiran P, Kashfi K, Ghasemi A. Vascular nitric oxide resistance in type 2 diabetes. Cell Death Dis. 2023 07 11; 14(7):410.
-
Kashfi K. Fifty Years of Diazeniumdiolate Research: A Tribute to Dr. Larry K. Keefer. Crit Rev Oncog. 2023; 28(1):47-55.
-
Martinez L, Thames E, Kim J, Chaudhuri G, Singh R, Pervin S. Increased sensitivity of African American triple negative breast cancer cells to nitric oxide-induced mitochondria-mediated apoptosis. BMC Cancer. 2016 07 29; 16:559.
-
Vannini F, Chattopadhyay M, Kodela R, Rao PPN, Kashfi K. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling. Redox Biol. 2015 Dec; 6:318-325.
-
Kashfi K, Chattopadhyay M, Kodela R. NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties. Redox Biol. 2015 Dec; 6:287-296.
-
Crassous PA, Couloubaly S, Huang C, Zhou Z, Baskaran P, Kim DD, Papapetropoulos A, Fioramonti X, Dur?n WN, Beuve A. Soluble guanylyl cyclase is a target of angiotensin II-induced nitrosative stress in a hypertensive rat model. Am J Physiol Heart Circ Physiol. 2012 Sep 01; 303(5):H597-604.
-
Chattopadhyay M, Kodela R, Olson KR, Kashfi K. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochem Biophys Res Commun. 2012 Mar 16; 419(3):523-8.
-
Jain S, Tran S, El Gendy MA, Kashfi K, Jurasz P, Vel?zquez-Mart?nez CA. Nitric oxide release is not required to decrease the ulcerogenic profile of nonsteroidal anti-inflammatory drugs. J Med Chem. 2012 Jan 26; 55(2):688-96.